The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Resource: Utilizing DATATOP Biospecimens, 2011Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease
Objective/Rationale:
We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus... -
Resource: Utilizing DATATOP Biospecimens, 2011C-type Natriuretic Peptide (CNP): A Putative Biomarker of Neuronal Damage in Parkinson's Disease
Objective/Rationale:
CNP is a peptide produced by brain tissues where it acts to promote growth of nerve cells and their connections. Recent research in healthy humans has identified high... -
Rapid Response Innovation Awards, 2011Direct Reprogramming of Cells into Dopamine Neurons
Objective/Rationale:
The availability of dopaminergic neurons for in-depth study or therapeutic replacement approaches has traditionally been limited. We aim to reprogram cells into dopaminergic... -
Rapid Response Innovation Awards, 2011Whole Exome Sequencing in an Amish Parkinson's Disease Pedigree
Objective/Rationale:
Although there is strong evidence to suggest genetics plays a role in Parkinson’s disease, the majority of the genes involved in Parkinson’s disease remain unidentified. We... -
LRRK2 Target Engagement Ligand, 2011Evaluating Novel Small Molecule Inhibitors of LRRK2 to Deliver PET Ligands
Objective/Rationale:
The exciting discovery of activating mutations in the LRRK2 kinase in familial PD patients, coupled with the emergence of kinase inhibitors as a new class of efficacious drugs... -
Rapid Response Innovation Awards, 2011Developing a Human Neural Model for Parkinson's Disease
Objective/Rationale:
Advances in the knowledge and treatment of Parkinson’s disease (PD) are limited by the inability to obtain, grow and study neural cells from the brains of living patients. Small...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.